TENX - Tenax Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
6.80
-0.05 (-0.73%)
As of 1:31PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close6.85
Open6.65
Bid6.71 x 100
Ask6.90 x 1500
Day's Range6.65 - 6.90
52 Week Range4.41 - 15.20
Volume3,284
Avg. Volume29,455
Market Cap9.885M
Beta1.17
PE Ratio (TTM)N/A
EPS (TTM)-4.77
Earnings DateJul 27, 2015 - Aug 6, 2015
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
Trade prices are not sourced from all markets
  • Has Tenax Therapeutics Inc (NASDAQ:TENX) Improved Earnings Growth In Recent Times?
    Simply Wall St.last month

    Has Tenax Therapeutics Inc (NASDAQ:TENX) Improved Earnings Growth In Recent Times?

    For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Tenax Therapeutics Inc’s (NASDAQ:TENX) track record on a high level, toRead More...

  • Zacks Small Cap Research2 months ago

    TENX: Tenax 1Q:18 Results

    By John Vandermosten, CFA NASDAQ:TENX READ THE FULL RESEARCH REPORT First Quarter 2018 Review 2018 began a new chapter for Tenax Therapeutics (NASDAQ:TENX). In January, Tenax announced its plan to advance ...

  • Business Wire2 months ago

    Tenax Therapeutics Announces Appointment of Anthony A. DiTonno as CEO

    Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced the Company has selected board member Anthony A. DiTonno to be its next Chief Executive Officer, effective June 1, 2018. Michael Jebsen, Tenax’s current Interim Chief Executive Officer and Chief Financial Officer, will remain serving as Tenax’s Chief Financial Officer.

  • While merger a possibility, Tenax pushes forward with new trial
    American City Business Journals2 months ago

    While merger a possibility, Tenax pushes forward with new trial

    Amid an ongoing review of strategic alternatives, Morrisville-based Tenax Therapeutics (Nasdaq: TENX) is getting underway with an important new clinical trial.

  • Business Wire2 months ago

    Tenax Therapeutics Announces Study Design for Phase 2 Trial of Levosimendan in PH-HFpEF Patients

    Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on providing products to address conditions with significant unmet medical needs, today announced the registration of their Phase 2 clinical trial in the use of levosimendan for treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF) on ClinicalTrials.gov. The Phase 2 PH-HFpEF study is a multi-center, double blind, randomized, placebo-controlled clinical trial that is testing the hypothesis that chronic, intermittent doses of levosimendan will significantly improve hemodynamic measures of exercise performance in patients suffering from Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.

  • Why You Need To Look At This Factor Before Buying Tenax Therapeutics Inc (NASDAQ:TENX)
    Simply Wall St.2 months ago

    Why You Need To Look At This Factor Before Buying Tenax Therapeutics Inc (NASDAQ:TENX)

    If you are looking to invest in Tenax Therapeutics Inc’s (NASDAQ:TENX), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...

  • How Do Analysts See Tenax Therapeutics Inc (NASDAQ:TENX) Performing In The Next Couple Of Years?
    Simply Wall St.3 months ago

    How Do Analysts See Tenax Therapeutics Inc (NASDAQ:TENX) Performing In The Next Couple Of Years?

    Tenax Therapeutics Inc’s (NASDAQ:TENX) latest earnings announcement in December 2017 confirmed that losses became smaller relative to the prrior year’s level – great news for investors Today I want toRead More...

  • Zacks Small Cap Research3 months ago

    TENX: New Indication for Levosimendan

    Levosimendan is a calcium sensitizer and K-ATP channel activator that can improve systolic and diastolic function of the heart as well as provide vasodilatory effects through its ability to relax vascular smooth muscle. This mechanism of action has been shown to lead to important improvements in cardiovascular hemodynamics in previous heart failure studies, including increased cardiac output and reduction in pulmonary capillary wedge pressure which could be very helpful in correcting the reduced cardiac output and pulmonary congestion often seen in PH-HFpEF patients. It is also important to note that Levosimendan has been shown to improve right heart function as well as reduce pulmonary vascular resistance in various patient populations.

  • Benzinga4 months ago

    Finding Breakouts And Avoiding Fakeouts In A Market At War With Itself

    After a few weeks of travel culminating in last week’s Inner Circle Conference in Orlando , I’ve returned to a market filled with extremes . There is a lot of optimism and a healthy dose of anxiety riling ...

  • Amid strategic review, Tenax gets go-ahead from FDA
    American City Business Journals4 months ago

    Amid strategic review, Tenax gets go-ahead from FDA

    Amid an ongoing review of strategic alternatives announced in April of last year, Morrisville-based Tenax Therapeutics has nabbed an important go-ahead from the U.S. Food and Drug Administration.

  • Benzinga4 months ago

    Benzinga's Top Analyst Calls From April 5, 2018

    These headlines first appeared on Benzinga Pro . DA Davidson says Cadence Design Systems Inc (NASDAQ: CDNS )’s business strength is not reflected in its weak stock performance, upgrades from Neutral to ...

  • ACCESSWIRE4 months ago

    This $3 Medical Device Stock be Worth $9-14 with Impending Product Launch

    - Cardiology interventions and diagnostics are a big market, and the new field of remote monitoring, for arrhythmias and heart trouble, is a rapidly expanding component. Better remote monitoring technology ...

  • Tenax Therapeutics Inc’s (NASDAQ:TENX) Shift From Loss To Profit
    Simply Wall St.4 months ago

    Tenax Therapeutics Inc’s (NASDAQ:TENX) Shift From Loss To Profit

    Tenax Therapeutics Inc’s (NASDAQ:TENX): Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in theRead More...

  • Business Wire4 months ago

    Tenax Therapeutics Announces Results of Pre-IND Meeting with FDA for Phase 2 Study of Levosimendan in PH-HFpEF Patients

    Tenax Therapeutics, Inc.  , a specialty pharmaceutical company focused on providing products to address conditions with significant unmet medical needs, today announced the results of its pre-Investigational New Drug meeting with the United States Food & Drug Administration , where the FDA addressed the Company’s questions and provided guidance on its upcoming Phase 2 clinical trial in the use of levosimendan ...

  • Business Wire4 months ago

    Tenax Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

    Tenax Therapeutics, Inc.  , a specialty pharmaceutical company focused on providing products to address conditions with significant unmet medical needs, today announced that it has regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550 .

  • With A -97.88% Earnings Drop Lately, Did Tenax Therapeutics Inc (NASDAQ:TENX) Underperform Its Industry?
    Simply Wall St.5 months ago

    With A -97.88% Earnings Drop Lately, Did Tenax Therapeutics Inc (NASDAQ:TENX) Underperform Its Industry?

    For long term investors, improvement in profitability and outperformance against the industry can be important characteristics in a stock. In this article, I will take a look at Tenax TherapeuticsRead More...

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Stocks to Watch: Novavax and Tenax Therapeutics

    NEW YORK, NY / ACCESSWIRE / March 2, 2018 / Novavax shares soared higher on Thursday after the company revealed positive data from a trial on its flu vaccine NanoFlu. Shares of Tenax Therapuetics also ...

  • Business Wire5 months ago

    Tenax Therapeutics Announces New Scientific Publication of Preclinical Data Provides Additional Evidence of Levosimendan Treatment Effects in Pulmonary Hypertension

    Tenax Therapeutics, Inc.  today announced the publication of a positive preclinical study of levosimendan conducted by Hansen et al in the March 1, 2018, issue of Pulmonary Circulation.

  • Business Wire5 months ago

    Tenax Therapeutics Announces Reverse Stock Split

    Tenax Therapeutics, Inc.  , a specialty pharmaceutical company focused on providing products to address conditions with significant unmet medical needs, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-20.

  • Business Wire5 months ago

    World-Recognized Experts Join Tenax Therapeutics’ Scientific Advisory Board to Guide New Phase 2 Study

    Tenax Therapeutics, Inc. a leading specialty pharmaceutical company focused on providing products to address conditions with significant unmet medical needs, today announced the appointment of three internationally recognized medical experts in the fields of pulmonary hypertension and heart failure with preserved ejection fraction to its Scientific Advisory Board for the company’s planned Phase 2 clinical ...

  • Business Wire6 months ago

    Tenax Therapeutics Announces Plan to Develop Levosimendan for a Pulmonary Hypertension Indication with No FDA Approved Therapies

    Tenax Therapeutics, Inc.  today announced plans to advance the development of levosimendan for the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction .

  • Does Zero-Debt Make Tenax Therapeutics Inc (NASDAQ:TENX) A Financially Strong Company?
    Simply Wall St.7 months ago

    Does Zero-Debt Make Tenax Therapeutics Inc (NASDAQ:TENX) A Financially Strong Company?

    Tenax Therapeutics Inc (NASDAQ:TENX), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is TENXRead More...

  • Zacks Small Cap Researchlast year

    TENX: FDA Response on Levosimendan

    By John Vandermosten, CFA NASDAQ:TENX On July 28, Tenax Therapeutics, Inc. (NASDAQ:TENX) announced the FDA’s response to their May pre-IND meeting on May 10th.  The meeting was held to review data regarding ...

  • Business Wirelast year

    Tenax Therapeutics Provides Regulatory Update on Levosimendan

    Tenax Therapeutics, Inc. , a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today provides a regulatory update following discussions with the U.S.